Literature DB >> 31064790

Recurrence of herpes simplex virus endotheliitis in a Descemet membrane endothelial keratoplasty graft: mimicking fungal interface infection.

Samar K Basak1, Soham Basak1.   

Abstract

Recurrence of herpes simplex virus (HSV) keratitis is a problem of keratoplasty and the prognosis is often poor in spite of oral acyclovir (ACV) prophylaxis. This 64-year-old woman was a known case of recurrent HSV endotheliitis with irreversible corneal oedema in the left eye for 2 years. She underwent Descemet membrane endothelial keratoplasty with intraocular lens implantation under perioperative oral ACV and prednisolone. After 4 weeks, her cornea cleared with the best-corrected vision of 6/9. After 2.5 months, she presented with sudden photophobia and visual loss. An increasing focal endothelial lesion was noticed even after oral ACV. Suspecting fungal interface infection, anterior chamber tap was done for PCR for panfungal and viruses. It was only positive for HSV. Oral ACV was changed to oral valacyclovir. The patient responded dramatically within 2 weeks, and after 12 weeks, the lesion disappeared completely, leaving behind a faint scar with 6/9 p vision. Oral valacyclovir, a prodrug of ACV, may work better than oral ACV. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  anterior chamber; herpes simplex virus; transplantation

Mesh:

Substances:

Year:  2019        PMID: 31064790      PMCID: PMC6506042          DOI: 10.1136/bcr-2019-229441

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  15 in total

1.  Descemet membrane endothelial keratoplasty versus descemet stripping automated endothelial keratoplasty.

Authors:  Theofilos Tourtas; Kathrin Laaser; Bjoern O Bachmann; Claus Cursiefen; Friedrich E Kruse
Journal:  Am J Ophthalmol       Date:  2012-03-06       Impact factor: 5.258

2.  Recurrence and rejection rates following corneal transplantation for herpes simplex keratitis.

Authors:  J A Lomholt; K Baggesen; N Ehlers
Journal:  Acta Ophthalmol Scand       Date:  1995-02

3.  Fungal Interface Keratitis After Descemet Membrane Endothelial Keratoplasty.

Authors:  Victor A Augustin; Julia M Weller; Friedrich E Kruse; Theofilos Tourtas
Journal:  Cornea       Date:  2018-11       Impact factor: 2.651

4.  Descemet membrane endothelial keratoplasty for corneal decompensation caused by herpes simplex virus endotheliitis.

Authors:  Fatema Asi; Georgia Milioti; Berthold Seitz
Journal:  J Cataract Refract Surg       Date:  2018-01       Impact factor: 3.351

5.  Epidemiological and microbiological diagnosis of suppurative keratitis in Gangetic West Bengal, eastern India.

Authors:  Samar K Basak; Sukumar Basak; Ayan Mohanta; Arup Bhowmick
Journal:  Indian J Ophthalmol       Date:  2005-03       Impact factor: 1.848

6.  Descemet Stripping Automated Endothelial Keratoplasty Outcomes in Patients With Cytomegalovirus Endotheliitis.

Authors:  Ester Fernández López; Elsie Chan
Journal:  Cornea       Date:  2017-01       Impact factor: 2.651

Review 7.  Corneal endotheliitis.

Authors:  Takashi Suzuki; Yuichi Ohashi
Journal:  Semin Ophthalmol       Date:  2008 Jul-Aug       Impact factor: 1.975

Review 8.  Review of clinical and basic approaches to corneal endotheliitis.

Authors:  Yoshitsugu Inoue
Journal:  Cornea       Date:  2014-11       Impact factor: 2.651

9.  Preliminary clinical results of Descemet membrane endothelial keratoplasty.

Authors:  Gerrit R J Melles; T San Ong; Bob Ververs; Jacqueline van der Wees
Journal:  Am J Ophthalmol       Date:  2007-12-03       Impact factor: 5.258

10.  Acyclovir therapy in prevention of recurrent herpetic keratitis following penetrating keratoplasty.

Authors:  Sudipta Ghosh; Vishal Jhanji; Ecosse Lamoureux; Hugh R Taylor; Rasik B Vajpayee
Journal:  Am J Ophthalmol       Date:  2008-02       Impact factor: 5.258

View more
  1 in total

Review 1.  Ocular manifestations of herpes simplex virus.

Authors:  Gabriel S Valerio; Charles C Lin
Journal:  Curr Opin Ophthalmol       Date:  2019-11       Impact factor: 3.761

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.